Compare Ginkgo Bioworks Holdings Inc (DNA) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Lumen Technologies Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Lumen Technologies Inc trades at $5.28 (market cap $5.73B). The key difference: Lumen Technologies Inc is far larger — about 7.5× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Lumen Technologies Inc for 40 Days on average.
| DNA | LUMN | |
|---|---|---|
Market Cap | $763.64M | $5.73B |
Volume | 3,204,177 | 17,079,799 |
Sector | Health | Media |
52-Week High | $15.83 | $11.83 |
52-Week Low | $5.48 | $5.53 |
Typical Hold Time | 7 Days | 40 Days |
Enterprise Value | $865.59M | $17.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
LUMN trades at $5.56, down 5.92% on the day, reflecting ongoing investor caution amid weak profitability and high debt. The stock shows a bearish technical trend with key support at $5.00, while fundamentals reveal declining revenue, negative net income margins, and a challenging turnaround effort. Recent news highlights a Nasdaq listing move and AI-focused networking initiatives, but legacy telecom declines persist.
Outlook remains speculative with high execution risk; the company's deep value (P/S 0.47) and AI growth potential contrast with consistent losses and substantial leverage. Analyst consensus is Reduce, with 60.7% Hold ratings, signaling limited near-term confidence despite strategic pivots.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
